Delcath Announced Changes To Board Of Directors
NEW YORK, July 9, 2012 /PRNewswire/ -- Delcath Systems, Inc. (NASDAQ: DCTH), a specialty pharmaceutical and medical device company focused on oncology, announced today the appointment of pharmaceutical industry veterans Laura A. Brege and Tasos G. Konidaris to the Company's expanded Board of Directors, and the retirement of Robert B. Ladd, member of the Company's Board of Directors since 2006. Mr. Ladd's resignation became effective as of July 3, 2012, and the appointment of the new directors became effective as of July 5, 2012. The changes increase the size of the Board of Directors from seven to eight. Both Ms. Brege and Mr. Konidaris will serve as Class I directors with terms expiring at the 2013 annual stockholder meeting.
Ms. Brege brings more than 30 years of experience in biotechnology and venture capital sectors to the Board. She has successfully led the strategic expansion of companies and been part of developing and implementing the worldwide commercial strategy to prepare for the launch of a new drug. Mr. Konidaris has more than 20 years of finance and operational experience in the global pharmaceutical, medical technology and business information industries.
"Laura Brege and Tasos Konidaris possess significant financial and health care backgrounds, making them strong additions to our board," said Dr. Harold S. Koplewicz, Chairman of Delcath's Board of Directors. "Their experience with global product launches and partnership development together with their track record of increasing shareholder value will be invaluable assets to us as we continue to expand our commercialization efforts for our Hepatic CHEMOSAT® Delivery System globally."
Robert Ladd was an early champion of the potential of chemosaturation therapy, first as a Delcath investor and as a member of the Delcath Board of Directors since 2006. From his position on